Email the author Is Vaccination Related to The Cure Rate of COVID-19 Patients with Comorbidities?
Abstract
Background: Prior vaccination can prevent a COVID-19 patient from falling into moderate, severe, and critical conditions. The effect of vaccination on COVID-19 patients’ recovery has been widely studied. However, its correlation in critically severe COVID-19 patients with comorbidity has not been fully understood yet. This study aims to determine the correlation of vaccination in critically severe COVID-19 patients with comorbidity of hypertension and/or Diabetes Mellitus (DM).
Methods: A retrospective cohort study was conducted in critically severe COVID-19 patients with hypertension and/or DM treated in Dr. Moewardi Hospital, Surakarta, Indonesia from March 2021 to September 2021. The data were taken from patients’ medical records. We analyzed all data statistically with Chi-Square and fisher's exact test, and a p-value of < 0.05 was considered significant.
Results: There were 489 patients included in our study, 247 patients with hypertension and DM, and 242 patients without comorbidities. Vaccination status was significantly associated with the cure rate of critically severe COVID- 19 patients with hypertension (p=0.018), but not with DM (p=0.606). There was no significant association between age to the cure rate of critically severe COVID-19 patients with hypertension and DM (p=0.953). Vaccination status was related among patients with comorbidities and without comorbidities (p<0.001).
Conclusion: Vaccination was significantly correlated the cure rate of moderate to critically severe COVID-19 patients with hypertension and without comorbidities.
Keywords
Full Text:
PDFReferences
World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. Geneva; 2020 [cited 2021 Jan 31]. Available from: https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)
World Health Organization. Coronavirus Disease (COVID-19) Treatment Guidelines [Internet]. National Institutes of Health. 2020 [cited 2021 Jan 31]. Available from: https://www.covid19treatmentguidelines.nih.gov/
Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, et al. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol. 2020;127:104371.
Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. Journal of Community Empowerment for Health. 2020;3(2):77–84.
Del Sole F, Farcomeni A, Loffredo L, Carnevale R, Menichelli D, Vicario T, et al. Features of severe COVID‐19: A systematic review and meta‐analysis. Eur J Clin Invest. 2020;50(10):e13378.
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–8.
Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. International Journal of Infectious Diseases. 2022;114:252–60.
Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron. N Engl J Med. 2022;386(14):1377–80.
Swamy S, Koch CA, Hannah-Shmouni F, Schiffrin EL, Klubo-Gwiezdzinska J, Gubbi S. Hypertension and COVID-19: Updates from the era of vaccines and variants. J Clin Transl Endocrinol [Internet]. 2022 Mar 1 [cited 2023 Jul 7];27:100285. Available from: /pmc/articles/PMC8645507/
Sun SH, Chen Q, Gu HJ, Yang G, Wang YX, Huang XY, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020;28(1):124-133.e4.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.
Zhang X, Yu J, Pan L ya, Jiang H yin. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. Pharmacol Res. 2020;158:104927.
Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19–systematic review, meta-analysis, and meta-regression. Journal of Stroke and Cerebrovascular Diseases. 2020;29(8):104949.
Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ace-inhibitors and arbs in covid-19 patients. Elife. 2020;9.
Singh AK, Gillies CL, Singh R, Singh A, Chudasama Y, Coles B, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes Metab. 2020;22(10):1915–24.
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318(5):E736–41.
Rao S, Lau A, So HC. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: A mendelian randomization analysis highlights tentative relevance of diabetes-related traits. Diabetes Care. 2020;43(7):1416–26.
Fernandez C, Rysä J, Almgren P, Nilsson J, Engström G, Orho-Melander M, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med. 2018;284(4):377–87.
Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews Endocrinology 2020 17:1. 2020;17(1):11–30.
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5.
Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, Felix SEB, et al. Coronavirus disease 2019 case surveillance — United States, January 22–May 30, 2020. Morbidity and Mortality Weekly Report. 2020;69(24):759–65.
Zhang ZL, Hou YL, Li DT, Li FZ. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2020;80(6):1–7.
DOI: https://doi.org/10.36497/jri.v43i3.324
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Mia Herdiyani Achmad, Reviono, Yusup Subagio Sutanto, Jatu Aphridasari, Windu Prasetyo
INDEXING & PARTNER
| Jurnal Respirologi Indonesia pISSN: 0853-7704 - eISSN: 2620-3162 Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia Phone: +62-21-2247-4845 Email: editor@jurnalrespirologi.org |  An official publication by the Indonesian Society of Respirology (ISR) |
 Creative Commons Attribution-ShareAlike 4.0 International License Statcounter |